Cargando…

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women

PURPOSE: Tamoxifen is an anti-estrogenic drug that is widely used for endocrine-dependent breast cancer as adjuvant hormonal therapy, and its use has been reported to be frequently associated with high levels of serum estradiol. Since the population of premenopausal women receiving tamoxifen therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Rena, Inokuchi, Masafumi, Ishikawa, Satoko, Myojo, Subaru, Iwadare, Junpei, Bono, Yukiko, Mizumoto, Yasunari, Nakamura, Mitsuhiro, Takakura, Masahiro, Iizuka, Takashi, Ohta, Tetsuo, Fujiwara, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539309/ https://www.ncbi.nlm.nih.gov/pubmed/26290804 http://dx.doi.org/10.1186/s40064-015-1223-0

Ejemplares similares

Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study
por: Yamazaki, Rena, et al.
Publicado: (2020)

Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase‐positive cells
por: Takakura, Masahiro, et al.
Publicado: (2017)

Subserous invasion of VEGF-C-producing cancer cells is a possible risk factor for ileal ulceration in the non-metastatic mucosal layer during bevacizumab-combined chemotherapy for recurrent ovarian cancer: A case report
por: Matsumoto, Takeo, et al.
Publicado: (2017)

A direct endoscopic approach for left-sided infrarenal para-aortic lymphadenectomy immediately after hysterectomy for endometrial cancer treatment: left dome formation (LDF)
por: Mizumoto, Yasunari, et al.
Publicado: (2019)

Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study
por: Kayahashi, Kayo, et al.
Publicado: (2021)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3‐dependent pathway
por: Matsumoto, Takeo, et al.
Publicado: (2023)

Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma
por: Obata, Takeshi, et al.
Publicado: (2017)

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
por: Eriksson, Mikael, et al.
Publicado: (2021)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen
por: Lehn, S, et al.
Publicado: (2009)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

Uterine Deletion of Bmal1 Impairs Placental Vascularization and Induces Intrauterine Fetal Death in Mice
por: Ono, Masanori, et al.
Publicado: (2022)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Novel strategy of ovarian cancer implantation: Pre‐invasive growth of fibrin‐anchored cells with neovascularization
por: Matsuoka, Ayumi, et al.
Publicado: (2019)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study
por: Pala, Şehmus, et al.
Publicado: (2015)

Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report
por: INOKUCHI, MASAFUMI, et al.
Publicado: (2014)

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
por: Cohen, I., et al.
Publicado: (1994)

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
por: Brennan, Donal J, et al.
Publicado: (2011)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
por: Ryu, Ki-Jin, et al.
Publicado: (2022)

Ovarian hyperstimulation syndrome
por: Kumar, Pratap, et al.
Publicado: (2011)

Ovarian and intellectual hyperstimulation
por: Quaas, Alexander M.
Publicado: (2021)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
por: Lundgren, Christine, et al.
Publicado: (2023)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis
por: Mahajan, Nalini, et al.
Publicado: (2015)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Activation-induced cytidine deaminase is a possible regulator of cross-talk between oocytes and granulosa cells through GDF-9 and SCF feedback system
por: Iizuka, Takashi, et al.
Publicado: (2021)

Ovarian Hyperstimulation Syndrome, the Master of Disguise?
por: Ironside, Emily Charlotte, et al.
Publicado: (2015)

Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers
por: Takakura, M, et al.
Publicado: (2012)

Premenopausal osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ehcjahtmid3cof1lefl9auqcq